Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 4
2017 7
2018 5
2019 5
2020 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Green JB, et al. N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. N Engl J Med. 2015. PMID: 26052984 Free article. Clinical Trial.
Pancreatic Safety of Sitagliptin in the TECOS Study.
Buse JB, Bethel MA, Green JB, Stevens SR, Lokhnygina Y, Aschner P, Grado CR, Tankova T, Wainstein J, Josse R, Lachin JM, Engel SS, Patel K, Peterson ED, Holman RR; TECOS Study Group. Buse JB, et al. Diabetes Care. 2017 Feb;40(2):164-170. doi: 10.2337/dc15-2780. Epub 2016 Sep 14. Diabetes Care. 2017. PMID: 27630212 Free PMC article. Clinical Trial.
Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.
Josse RG, Majumdar SR, Zheng Y, Adler A, Bethel MA, Buse JB, Green JB, Kaufman KD, Rodbard HW, Tankova T, Westerhout CM, Peterson ED, Holman RR, Armstrong PW; TECOS Study Group. Josse RG, et al. Diabetes Obes Metab. 2017 Jan;19(1):78-86. doi: 10.1111/dom.12786. Epub 2016 Oct 6. Diabetes Obes Metab. 2017. PMID: 27607571 Clinical Trial.
Progression of glucose-lowering diabetes therapy in TECOS.
Bethel MA, Engel SS, Stevens SR, Lokhnygina Y, Ding J, Josse RG, Alvarsson M, Hramiak I, Green JB, Peterson ED, Holman RR; TECOS Study Group. Bethel MA, et al. Endocrinol Diabetes Metab. 2018 Dec 22;2(1):e00053. doi: 10.1002/edm2.53. eCollection 2019 Jan. Endocrinol Diabetes Metab. 2018. PMID: 30815579 Free PMC article.
Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Reed SD, Li Y, Leal J, Radican L, Adler AI, Alfredsson J, Buse JB, Green JB, Kaufman KD, Riefflin A, Van de Werf F, Peterson ED, Gray AM, Holman RR; TECOS Study Group. Reed SD, et al. Diabetes Obes Metab. 2018 Jul;20(7):1732-1739. doi: 10.1111/dom.13292. Epub 2018 Apr 20. Diabetes Obes Metab. 2018. PMID: 29573215
International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS.
Bhatt AS, Luo N, Solomon N, Pagidipati NJ, Ambrosio G, Green JB, McGuire DK, Standl E, Cornel JH, Halvorsen S, Lopes RD, White HD, Holman RR, Peterson ED, Mentz RJ; TECOS Study Group. Bhatt AS, et al. Am Heart J. 2019 Dec;218:57-65. doi: 10.1016/j.ahj.2019.08.016. Epub 2019 Aug 28. Am Heart J. 2019. PMID: 31707329 Clinical Trial.
Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial.
McAlister FA, Zheng Y, Westerhout CM, Buse JB, Standl E, McGuire DK, Van de Werf F, Green JB, Armstrong PW, Holman RR; TECOS Study Group. McAlister FA, et al. Eur J Heart Fail. 2020 Nov;22(11):2026-2034. doi: 10.1002/ejhf.1958. Epub 2020 Jul 28. Eur J Heart Fail. 2020. PMID: 32621557 Free article. Clinical Trial.
20 results